# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Gena Wang maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $27 t...
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(...
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investiga...
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Equal-Weight and raises the price tar...